Reproductive Endocrinology Practice Questions

Q: A 17-year-old patient presents with primary amenorrhea. On physical examination, she is 5'8" tall, has no breast development, and no axillary or pubic hair. Pelvic examination reveals a normally developed vagina, a visible cervix, a palpable uterus, and normal ovaries. The physician decides to test her sense of smell. What is the physician suspecting?

Kallman's syndrome. ### Explanation **Correct Option: B. Kallmann Syndrome** The clinical presentation of **primary amenorrhea** combined with a **lack of secondary sexual characteristics** (no breast development, no axillary/pubic hair) indicates a failure of the Hypothalamic-Pituitary-Ovarian (HPO) axis. Kallmann Syndrome is a form of **hypogonadotropic hypogonadism** caused by the failure of GnRH-secreting neurons to migrate from the olfactory placode to the hypothalamus. This migration defect is often associated with the hypoplasia or aplasia of the olfactory bulbs, leading to **anosmia** (loss of smell) or hyposmia. Testing the sense of smell is the classic clinical bedside maneuver to differentiate Kallmann syndrome from other forms of hypogonadotropic hypogonadism. **Why other options are incorrect:** * **Asherman’s Syndrome:** This involves intrauterine adhesions (usually post-curettage). Patients have normal secondary sexual characteristics and ovaries; the defect is in the end-organ (uterus). * **Stein-Leventhal Syndrome (PCOS):** Typically presents with secondary amenorrhea, hirsutism, and obesity. Patients have normal breast development and pubic hair. * **Sheehan’s Syndrome:** This is postpartum pituitary necrosis following severe obstetric hemorrhage. It presents as secondary amenorrhea and failure of lactation in women who have already achieved puberty. **NEET-PG High-Yield Pearls:** * **Genetics:** Most commonly X-linked recessive (KAL1 gene mutation). * **Clinical Triad:** Primary amenorrhea + Delayed puberty + Anosmia. * **Hormonal Profile:** Low GnRH → Low FSH/LH → Low Estrogen (Hypo-Hypo). * **Imaging:** MRI may show absent or hypoplastic olfactory bulbs. * **Note:** While the question mentions "normal ovaries" and "palpable uterus," these organs are anatomically present but remain prepubertal/infantile due to the lack of hormonal stimulation.

Q: Selective estrogen receptor modulators (SERMs) are used as add-back therapy concurrently with GnRH agonist to:

Prevent bone loss. ### Explanation **Concept Overview:** GnRH agonists (e.g., Leuprolide) induce a state of **"pseudomenopause"** by downregulating pituitary GnRH receptors, leading to profound hypoestrogenism. While effective for treating endometriosis and leiomyoma, long-term use (beyond 6 months) is limited by severe side effects, most notably **accelerated bone mineral density (BMD) loss** and vasomotor symptoms. **Why Option B is Correct:** To mitigate these side effects, **"Add-back therapy"** is employed. While traditional add-back therapy uses low-dose estrogen/progestin, **SERMs (like Raloxifene)** are increasingly used. Raloxifene acts as an **estrogen agonist in the bone**, stimulating osteoblastic activity and inhibiting osteoclasts, thereby **preventing bone loss** without stimulating the endometrium or breast tissue. **Why Other Options are Incorrect:** * **Option A:** GnRH agonists alone cause leiomyoma shrinkage. Adding a SERM does not synergistically increase shrinkage; in fact, the goal of add-back is to manage side effects, not enhance primary efficacy. * **Option C:** While estrogen/progestin add-back treats vasomotor symptoms (hot flashes), **SERMs (especially Raloxifene) can actually worsen hot flashes** due to their estrogen antagonist effect in the CNS. * **Option D:** SERMs are associated with an **increased risk** of venous thromboembolism (VTE), similar to oral contraceptives; they do not decrease this risk. **High-Yield Clinical Pearls for NEET-PG:** * **The "Estrogen Threshold Hypothesis":** There is a therapeutic window (estrogen levels of 30–45 pg/mL) where bone loss is prevented, but the growth of endometriosis/fibroids is not stimulated. * **Indications for Add-back:** Usually started if GnRH agonist therapy is planned for **>6 months**. * **Raloxifene vs. Tamoxifen:** Raloxifene is preferred in add-back therapy because it is an antagonist at the uterus (no risk of endometrial hyperplasia), unlike Tamoxifen.

Q: Which of the following medications is NOT used for the management of hirsutism in females?

Oxandrolone. **Explanation:** Hirsutism is defined as the presence of terminal hair in females in a male-pattern distribution, typically caused by hyperandrogenism. The management involves blocking androgen production or inhibiting androgen action at the hair follicle. **Why Oxandrolone is the Correct Answer:** **Oxandrolone** is an **anabolic steroid** (a synthetic derivative of testosterone). Instead of treating hirsutism, it would actually **cause or worsen** it as a side effect (virilization). It is medically used to promote weight gain after surgery or chronic trauma, but it is contraindicated in the management of hyperandrogenic symptoms. **Analysis of Incorrect Options:** * **Spironolactone (Option A):** An aldosterone antagonist that also acts as a competitive androgen receptor blocker and inhibits 5-alpha reductase. It is often the first-line medical treatment for hirsutism. * **Finasteride (Option C):** A 5-alpha reductase inhibitor that prevents the conversion of Testosterone to the more potent Dihydrotestosterone (DHT). It is highly effective in reducing terminal hair growth. * **Flutamide (Option D):** A pure non-steroidal anti-androgen that competes with testosterone and DHT for binding to the androgen receptor. While effective, its use is limited by potential hepatotoxicity. **NEET-PG High-Yield Pearls:** * **Ferriman-Gallwey Score:** Used to clinically grade hirsutism; a score ≥8 is generally considered diagnostic. * **Combined Oral Contraceptives (COCs):** Usually the first-line therapy for hirsutism as they suppress ovarian androgen production and increase Sex Hormone Binding Globulin (SHBG). * **Eflornithine:** A topical cream used as an adjuvant; it inhibits the enzyme ornithine decarboxylase in hair follicles to slow hair growth. * **Contraindication:** All anti-androgens (Options A, C, D) are contraindicated in pregnancy due to the risk of feminization of a male fetus.

Q: A 35-year-old lady has not had her menses for the last 4 months. She has high serum FSH and LH levels with low estradiol. What is the likely cause?

Premature menopause. ### **Explanation** The clinical presentation of secondary amenorrhea (4 months) associated with **high gonadotropins (FSH and LH)** and **low estradiol** indicates **Hypergonadotropic Hypogonadism**. **1. Why Premature Menopause is Correct:** Premature menopause, or Premature Ovarian Insufficiency (POI), occurs when ovarian follicles are depleted or dysfunctional before age 40. In this state, the ovaries fail to produce estradiol. The lack of negative feedback from estradiol on the HPO axis leads to a compensatory rise in FSH and LH from the anterior pituitary. A serum **FSH level >40 IU/L** on two occasions is the diagnostic hallmark. **2. Analysis of Incorrect Options:** * **Panhypopituitarism:** This results in *Hypogonadotropic Hypogonadism*. Both FSH/LH and estradiol would be low because the pituitary fails to secrete gonadotropins. * **Polycystic Ovarian Disease (PCOS):** Characterized by an increased LH:FSH ratio (often 2:1 or 3:1) and normal or elevated estrogen levels. FSH is typically normal or low-normal, not high. * **Exogenous Estrogen Administration:** High levels of exogenous estrogen would exert negative feedback on the pituitary, resulting in **low** FSH and LH levels. **3. NEET-PG High-Yield Pearls:** * **Definition:** Menopause before age 40 is Premature Ovarian Insufficiency; before age 45 is Early Menopause. * **Most common chromosomal cause:** Turner Syndrome (45,X) or Mosaicism. * **Most common reversible cause:** Autoimmune oophoritis. * **Kariotype:** Mandatory in all women with POI under age 30 to rule out Y-chromosome material (risk of gonadoblastoma). * **Management:** Hormone Replacement Therapy (HRT) is essential until the natural age of menopause (approx. 50 years) to prevent osteoporosis and cardiovascular disease.

Q: In a patient with secondary amenorrhea who fails to achieve withdrawal bleeding after estrogen and progesterone therapy, the primary cause lies at which level?

Endometrium. ### Explanation The evaluation of secondary amenorrhea follows a stepwise approach. When a patient fails to bleed after a **Progesterone Challenge Test**, it indicates either low endogenous estrogen or an anatomical defect. To differentiate these, the **Estrogen-Progesterone (E+P) Challenge Test** is performed. **Why the Endometrium is the correct answer:** The E+P challenge involves administering exogenous estrogen to proliferate the endometrium, followed by progesterone to induce withdrawal bleeding. If the patient **fails to bleed** even after this combined therapy, it confirms that the "outflow tract" or the "target organ" is defective. This implies the endometrium is either absent, scarred, or unresponsive (e.g., **Asherman Syndrome** or **Genital Tuberculosis**). **Why other options are incorrect:** * **Hypothalamus (B) and Pituitary (A):** If the defect were at the level of the HPO axis (low GnRH or FSH/LH), the exogenous hormones provided in the test would have bypassed these levels and caused the endometrium to shed. A positive bleed in these cases would point toward hypothalamic/pituitary failure. * **Ovary (C):** Similarly, if the ovaries were failing (Premature Ovarian Failure), they would not be producing estrogen. However, the exogenous estrogen provided during the test would still cause the endometrium to proliferate and bleed. **High-Yield Clinical Pearls for NEET-PG:** * **Step 1:** Rule out pregnancy (most common cause of secondary amenorrhea). * **Step 2:** Progesterone Challenge Test (Checks endogenous estrogen and outflow tract). * **Step 3:** E+P Challenge Test (Checks endometrium/outflow tract patency). * **Asherman Syndrome:** The most common cause of a negative E+P challenge test in clinical practice. * **Genital TB:** A high-yield cause in the Indian context leading to end-stage uterine synechiae and a negative E+P test.

Q: Which of the following is the most likely diagnosis in a 27-year-old obese woman presenting with oligomenorrhea, infertility, and hirsutism?

Polycystic ovarian syndrome. **Explanation:** The clinical triad of **oligomenorrhea, infertility, and hirsutism** in an obese woman of reproductive age is the classic presentation of **Polycystic Ovarian Syndrome (PCOS)**. 1. **Why PCOS is correct:** PCOS is a common endocrine disorder characterized by hyperandrogenism (causing hirsutism and acne) and ovulatory dysfunction (leading to oligomenorrhea and infertility). Obesity is a frequent comorbid feature that exacerbates insulin resistance, a key driver in the pathogenesis of PCOS. Diagnosis is typically made using the **Rotterdam Criteria**, requiring two of three: oligo/anovulation, clinical/biochemical hyperandrogenism, and polycystic ovaries on ultrasound. 2. **Why other options are incorrect:** * **Endometriosis:** Typically presents with the "3 Ds": Dysmenorrhea, Dyspareunia, and Dyschezia. While it causes infertility, it does not cause hirsutism or oligomenorrhea. * **Pelvic Inflammatory Disease (PID):** Presents with pelvic pain, vaginal discharge, and fever. It can lead to tubal factor infertility but does not involve hormonal imbalances like hirsutism. * **Turner’s Syndrome (45,XO):** Patients typically present with **primary amenorrhea**, short stature, and webbed neck. They have streak ovaries and low estrogen, not the hyperandrogenism seen here. **High-Yield Clinical Pearls for NEET-PG:** * **LH:FSH Ratio:** Classically >2:1 or 3:1 (though no longer a diagnostic criterion). * **Gold Standard for Infertility:** Clomiphene citrate was historically first-line, but **Letrozole** (Aromatase inhibitor) is now the drug of choice for ovulation induction in PCOS. * **Metabolic Risk:** Increased risk of Type 2 Diabetes and **Endometrial Hyperplasia/Carcinoma** due to unopposed estrogen. * **String of Pearls:** Classic ultrasound appearance (12 or more follicles measuring 2-9 mm).

Q: A 16-year-old girl has not yet reached menarche. She has normal secondary sex characteristics, and visual inspection of her external genitalia is unremarkable. The patient is given progesterone and has withdrawal bleeding a few days later. What is the most likely diagnosis?

A constitutional delay in puberty. **Explanation:** The core concept in this case is the **Progesterone Challenge Test (PCT)**. A positive withdrawal bleed indicates two things: 1. The patient has an intact **outflow tract** (uterus, cervix, and vagina). 2. The patient has **adequate endogenous estrogen** to prime the endometrium. **Constitutional Delay in Puberty** is the most likely diagnosis because the patient has normal secondary sexual characteristics (indicating a functional Hypothalamic-Pituitary-Ovarian axis that has produced enough estrogen for breast development) and a positive PCT. In constitutional delay, the "biological clock" is simply set later, but the hormonal machinery is intact. **Analysis of Incorrect Options:** * **Primary Ovarian Disease (e.g., Premature Ovarian Failure):** These patients have low estrogen levels. Without estrogen priming, the endometrium does not proliferate, leading to a **negative** progesterone withdrawal bleed. * **Turner Syndrome (45,XO):** This is a form of hypergonadotropic hypogonadism characterized by streak ovaries. These patients typically present with primary amenorrhea, short stature, and a **lack** of secondary sexual characteristics/estrogen, resulting in a negative PCT. * **Destructive Hypothalamic Disorder:** Conditions like Kallmann syndrome or craniopharyngioma cause hypogonadotropic hypogonadism. The lack of GnRH leads to low FSH/LH and, consequently, low estrogen, resulting in a **negative** PCT. **Clinical Pearls for NEET-PG:** * **Positive PCT:** Confirms anovulation (usually PCOS or Constitutional Delay). * **Negative PCT:** Indicates either low estrogen (Hypothalamic/Ovarian failure) or an outflow tract obstruction (Asherman’s or Mullerian anomalies). * **Primary Amenorrhea Definition:** Absence of menarche by age 13 (no secondary sexual characteristics) or age 15 (with secondary sexual characteristics).

Q: Which of the following is not a cause for primary amenorrhea?

Sheehan's syndrome. ### Explanation The key to answering this question lies in distinguishing between **primary** and **secondary** amenorrhea. Primary amenorrhea refers to the failure to initiate menses by age 15 (with secondary sexual characteristics) or age 13 (without them). Secondary amenorrhea is the cessation of menses for >3 months in a previously regular cycle. **Why Sheehan’s Syndrome is the correct answer:** Sheehan’s syndrome is **postpartum pituitary necrosis** caused by severe obstetric hemorrhage and hypotension. Since it occurs as a complication of childbirth, the patient must have been menstruating and fertile previously. Therefore, it is a classic cause of **secondary amenorrhea**, not primary. **Analysis of Incorrect Options:** * **Kallmann’s Syndrome:** A form of hypogonadotropic hypogonadism caused by failure of GnRH-secreting neurons to migrate. It presents with primary amenorrhea and anosmia. * **Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome:** Characterized by Müllerian agenesis (absent uterus and upper 2/3 of the vagina). It is the second most common cause of primary amenorrhea; patients have a 46,XX karyotype and normal secondary sexual characteristics. * **Turner Syndrome (45,XO):** The most common cause of primary amenorrhea. It involves gonadal dysgenesis (streak ovaries), leading to hypergonadotropic hypogonadism. **NEET-PG High-Yield Pearls:** * **Most common cause of primary amenorrhea:** Turner Syndrome (45,XO). * **Most common cause of secondary amenorrhea:** Pregnancy (always rule this out first!). * **Sheehan’s Syndrome clinical hint:** Look for a history of "failure to lactate" followed by "failure to resume menses" after a traumatic delivery. * **MRKH vs. AIS:** In MRKH, the karyotype is 46,XX (ovaries present); in Androgen Insensitivity Syndrome (AIS), the karyotype is 46,XY (testes present).

Question 1

A 17-year-old patient presents with primary amenorrhea. On physical examination, she is 5'8" tall, has no breast development, and no axillary or pubic hair. Pelvic examination reveals a normally developed vagina, a visible cervix, a palpable uterus, and normal ovaries. The physician decides to test her sense of smell. What is the physician suspecting?

Accepted Answer

Kallman's syndrome

Answer

Asherman's syndrome

Answer

Stein-Leventhal syndrome

Answer

Sheehan's syndrome

Question 2

A newborn infant with ambiguous genitalia is found to have a 46, XX karyotype. All of the following are diagnostic possibilities EXCEPT?

Accepted Answer

Partial androgen resistance syndrome

Answer

21-hydroxylase deficiency

Answer

True hermaphroditism

Answer

Maternal virilizing tumor

Question 3

Selective estrogen receptor modulators (SERMs) are used as add-back therapy concurrently with GnRH agonist to:

Accepted Answer

Prevent bone loss

Answer

Increase shrinkage of leiomyoma

Answer

Avoid vasomotor symptoms

Answer

Decrease venous thromboembolism risks

Question 4

Which of the following medications is NOT used for the management of hirsutism in females?

Accepted Answer

Oxandrolone

Answer

Spironolactone

Answer

Finasteride

Answer

Flutamide

Question 5

A 35-year-old lady has not had her menses for the last 4 months. She has high serum FSH and LH levels with low estradiol. What is the likely cause?

Accepted Answer

Premature menopause

Answer

Panhypopituitarism

Answer

Polycystic ovarian disease

Answer

Exogenous estrogen administration

Question 6

In a patient with secondary amenorrhea who fails to achieve withdrawal bleeding after estrogen and progesterone therapy, the primary cause lies at which level?

Accepted Answer

Endometrium

Answer

Pituitary

Answer

Hypothalamus

Answer

Ovary

Question 7

A mother brings her 19-year-old daughter to your clinic with the complaint that she has not started menstruating. General examination reveals normally developed breasts and pubic hair. On pelvic examination, the vaginal ending is blind, and the uterus is not palpable. Which of the following do you suspect?

Accepted Answer

Mullerian agenesis

Answer

Asherman syndrome

Answer

Gonadal dysgenesis

Answer

Turner syndrome

Question 8

Which of the following is the most likely diagnosis in a 27-year-old obese woman presenting with oligomenorrhea, infertility, and hirsutism?

Accepted Answer

Polycystic ovarian syndrome

Answer

Endometriosis

Answer

Pelvic inflammatory disease

Answer

Turner's syndrome

Question 9

A 16-year-old girl has not yet reached menarche. She has normal secondary sex characteristics, and visual inspection of her external genitalia is unremarkable. The patient is given progesterone and has withdrawal bleeding a few days later. What is the most likely diagnosis?

Accepted Answer

A constitutional delay in puberty

Answer

Primary ovarian disease

Answer

Turner syndrome

Answer

A destructive hypothalamic disorder

Question 10

Which of the following is not a cause for primary amenorrhea?

Accepted Answer

Sheehan's syndrome

Answer

Kallmann's syndrome

Answer

Mayer Rokitansky Kuster Hauser syndrome

Answer

Turner syndrome

Reproductive Endocrinology — MCQs

Reproductive Endocrinology — MCQs

On this page

Practice by Chapter

Want unlimited practice?